SCA
AMRX icon

Snowden Capital Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Snowden Capital Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,561
Closed -$7K – 1072
2021
Q4 		$7K Buy
+1,561
New +$7.78K ﹤0.01% 1596

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Snowden Capital Advisors's AMRX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q1 2022, closing a stake of 1,561 shares — an estimated $7K sold.

Snowden Capital Advisors first reported a position in AMRX in Q4 2021 and held it in 1 quarter. The position peaked at $7K in Q4 2021. 168 funds tracked by Wall St. Rank hold AMRX as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Amneal Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 1,561 Amneal Pharmaceuticals shares in Q1 2022, an estimated $7K.
  • Snowden Capital Advisors first reported a position in Amneal Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Amneal Pharmaceuticals position peaked at $7K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.